RNS Number: 9039P Diaceutics PLC 24 May 2024

## Diaceutics PLC

## PDMR Shareholding/Share Incentive Plan and Total Voting Rights

Belfast and London, 24 May 2024 Diaceutics PLC (AIM: DXRX) leading technology and solutions provider to the pharma and biotech industry, has been notified that on 24 May 2024, Global Shares Trustees (UK) Limited (the "UK Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trus, have purchased ordinary shares of £0.002 in the capital of the Company ("Shares") on behalf of Susanne Munksted, Jordan Clark, Julie Browne, Nick Roberts and Jillian Beggs (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employeesThese purchases will be made each month until further notice.

In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.

As announced on 2 October 2023, application was made to AIM for a block listing of 1,500,000 Shares to facilitate the admission of the Shares to trading following the exercise of options inter alia under the SIP Schemes. Therefore, the matched share awards for the UK PDMRs, along with those for all other participants in the UK SIP Scheme, have been settled by the Company issuing 7,117 Shares on 24 May 2024 to the UK Trust. The Trust will hold these Shares on behalf of participants until they vest in accordance with the UK Scheme rules.

Following the issue of Shares on 24 May 2024, Diaceutics has 84,712,668 Shares in issue. This figure may be used by shareholders in the Company as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

## **Enquiries:**

Diaceutics PLCTel: +44 (0)28 9040 6500Nick Roberts, Chief Financial Officerinvestorrelations@diaceutics.com

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison Nick Harland Kate Hanshaw

Alma Strategic Communications
Tel: +44(0)20 3405 0205
Caroline Forde diaceutics@almastrategic.com

Kinvara Verdon

## **About Diaceutics**

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

Noti	fication of a Transaction purs	uant to Article 19(1) of Regulation (EU) No. 596/2014	
1	Details of the person discharging managerial responsibilities/person closely associated		
а.	Name	Susanne Munksted	
2	Reason for notification		
а.	Position/Status	Chief Precision Medicine Officer	
b.	Initial notification/ Amendment	Initial	
3	Details of the issuer, emi monitor	ssion allowance market participant, auction platform, auctioneer or auction	

а.	Name	Diaceutics PLC		
b.	LEI	213800VEWQBB39ZB8J81		
4		s): section to be repeated for (i) each type of instrument; (ii) each type of ; and (iv) each place where transactions have been conducted		
a.	Description of the financial instrument, type of instrument	Ordinary shares of £0.002 each		
	Identification Code	ISIN: GB00BJQTGV64		
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")		
C.	Price(s) and volume(s)	Share purchase:	Share purchase:	
		Price(s)	Volume(s)	
		1.2788 p	115	
		Conditional share	e award:	
		Price(s)	Volume(s)	
		Nil	115	
e.	Date of the transaction	Share purchase and Conditional share award: 24 May 2024		
		·		
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange		
		Conditional share award: Off-Market		
Notifi	cation of a Transaction pursu	eant to Article 19(1) of Pe	gulation (FII) No. 596	/2014
Notin	tation of a fransaction pursu	iant to Article 19(1) of Re	guiation (EO) NO. 330,	/2014
1	Details of the person disch	arging managerial respon	sibilities/person close	ely associated
а.	Name	Jordan Clark		
2	Reason for notification	<u> </u>		
а.	Position/Status	Chief Data Officer		
b.	Initial notification/	Initial		
	Amendment			
3	Details of the issuer, emis monitor	sion allowance market participant, auction platform, auctioneer or auction		
а.	Name	Diaceutics PLC		
b.	LEI	213800VEWQBB39ZB8J	81	
4	Details of the transaction( transaction; (iii) each date			nstrument; (ii) each type of een conducted
а.	Description of the financial instrument, type of instrument	Ordinary shares of £0.0	002 each	
	Identification Code	ISIN: GB00BJQTGV64		

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")

Share purchase:

Nature of the transaction

Price(s) and volume(s)

b.

С.

			Price(s)	Volume(s)	
			1.274 p	118	
			Matched share awa	rd:	
			Price(s)	Volume(s)	
			Nil	118	
e.	Date of the transaction	Shar	e purchase and Match	ned Share award: 24 May20	24
f.	Place of the transaction	Shar	e Purchase: AIM Mark	et of the London Stock Exch	ange
		Mato	hed Share Award: Off	-Market	

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014				
1	Details of the person discharging managerial responsibilities/person closely associated			
а.	Name	Julie Browne		
2	Reason for notification			
а.	Position/Status	Chief Operations Officer		
b.	Initial notification/ Amendment	Initial		
3	Details of the issuer, emiss monitor	ion allowance market participant, auction platform, auctioneer or auction		
а.	Name	Diaceutics PLC		
b.	LEI	213800VEWQBB39ZB8J81		
4		s): section to be repeated for (i) each type of instrument; (ii) each type of; and (iv) each place where transactions have been conducted		
a.	Description of the financial instrument, type of instrument	Ordinary shares of £0.002 each		
	Identification Code	ISIN: GB00BJQTGV64		
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")		
c.	Price(s) and volume(s)	Share purchase:		
		Price(s) Volume(s)		
		1.274 p 118		
		Matched share award:		
		Price(s) Volume(s)		
		Nil 118		
e.	Date of the transaction	Share purchase and Matched Share award: 24 May 2024		
-				

f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange
		Matched Share Award: Off-Market

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014				
1	Details of the person discharging managerial responsibilities/person closely associated			
а.	Name	Nick Roberts		
2	Reason for notification			
а.	Position/Status	Chief Finance Officer		
b.	Initial notification/ Amendment	Initial		
3	Details of the issuer, emiss monitor	ion allowance market participant, auction platform, auctioneer or auction		
а.	Name	Diaceutics PLC		
b.	LEI	213800VEWQBB39ZB8J81		
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
а.	Description of the financial instrument, type of instrument	Ordinary shares of £0.002 each		
	Identification Code	ISIN: GB00BJQTGV64		
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")		
C.	Price(s) and volume(s)	Share purchase:		
		Price(s) Volume(s)		
		1.274 p 118		
		Matched share award:		
		Price(s) Volume(s)		
		Nil 118		
e.	Date of the transaction	Share purchase and Matched Share award: 24 May 2024		
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange		
		Matched Share Award: Off-Market		
Notific	ation of a Transaction pursu	ant to Article 19(1) of Regulation (EU) No. 596/2014		
1	Details of the person disch	arging managerial responsibilities/person closely associated		
а.	Name	Jillian Beggs		
2	Reason for notification			

Chief Commercial Officer

Initial

Position/Status

Initial notification/

a. b.

	Amendment				
3	Details of the issuer, emis monitor	l sion allowance market participant, auction platform, auctioneer or auction			
а.	Name	Diaceutics PLC			
b.	LEI	213800VEWQBB39ZB8J81			
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted				
а.	Description of the financial instrument, type of instrument	l instrument,			
	Identification Code	ISIN: GB00BJQTGV64			
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")			
C.	Price(s) and volume(s)	Share purchase:			
		Price(s) Volume(s)			
		1.274 p 118			
		Matched share award:			
		Price(s) Volume(s)			
		Nil 118			
e.	Date of the transaction	Share purchase and Matched Share award: 24 May 2024			
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange  Matched Share Award: Off-Market			

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:msc.dec.">msc.dec.</a> www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <a href="Privacy Policy">Privacy Policy</a>.

END

TVRAIMJTMTATBLI